An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278

Trial Profile

An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Rilpivirine (Primary) ; Nucleotide reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2018.
    • 14 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 29 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top